Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update

Silo Pharma, Inc. (NASDAQ:SILO) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 shares, a growth of 58.6% from the March 31st total of 329,449 shares. Based on an average daily volume of 18,681,437 shares, the short-interest ratio is currently 0.0 days. Approximately 3.3% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silo Pharma in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Silo Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SILO. Geode Capital Management LLC lifted its stake in Silo Pharma by 134.6% in the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock worth $32,000 after acquiring an additional 53,309 shares during the period. Virtu Financial LLC purchased a new stake in Silo Pharma in the third quarter worth $74,000. DRW Securities LLC purchased a new stake in Silo Pharma in the fourth quarter worth $113,000. AdvisorShares Investments LLC lifted its stake in Silo Pharma by 64.3% in the fourth quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock worth $204,000 after acquiring an additional 234,629 shares during the period. Finally, Anson Funds Management LP purchased a new stake in Silo Pharma in the third quarter worth $657,000. Hedge funds and other institutional investors own 5.58% of the company’s stock.

Silo Pharma Price Performance

Shares of SILO stock opened at $0.50 on Monday. The stock has a fifty day moving average of $0.38 and a 200 day moving average of $0.41. Silo Pharma has a 52 week low of $0.22 and a 52 week high of $1.17. The firm has a market capitalization of $8.14 million, a price-to-earnings ratio of -0.93 and a beta of 0.35.

Silo Pharma (NASDAQ:SILO) last announced its quarterly earnings results on Friday, March 27th. The company reported $0.03 EPS for the quarter. Silo Pharma had a negative return on equity of 83.53% and a negative net margin of 5,870.83%.The company had revenue of $0.02 million during the quarter.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.